Eupraxia Pharmaceuticals (EPRX) Institutional Ownership $7.10 +0.16 (+2.31%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$7.00 -0.09 (-1.34%) As of 05/22/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Eupraxia Pharmaceuticals (NASDAQ:EPRX)Number ofInstitutional Buyers(last 12 months)29TotalInstitutional Inflows(last 12 months)$55.01MNumber ofInstitutional Sellers(last 12 months)6TotalInstitutional Outflows(last 12 months)$7.91M Get EPRX Insider Trade Alerts Want to know when executives and insiders are buying or selling Eupraxia Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data EPRX Institutional Buying and Selling by Quarter Eupraxia Pharmaceuticals Major Shareholders & Ownership History ExportReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/19/2026 Bank of America Corp DE268,221$1.94M0.0%+5.9%0.444% 5/19/2026 Ally Bridge Group NY LLC660,375$4.78M3.9%+66.0%1.093% 5/18/2026 Royal Bank of Canada261,376$1.89M0.0%+33.2%0.433% 5/18/2026 Redmile Group LLC700,000$5.07M0.3%N/A1.158% 5/18/2026 Rubric Capital Management LP691,170$5.00M0.1%N/A1.144% 5/16/2026 SummitTX Capital L.P.327,997$2.38M0.1%+86.4%0.543% 5/15/2026 Affinity Asset Advisors LLC1,589,005$11.50M0.6%+429.7%2.629% 2/18/2026 XTX Topco Ltd16,180$122K0.0%N/A0.045% 2/18/2026 Ikarian Capital LLC610,000$4.61M0.4%N/A1.696% 2/18/2026 Squadron Capital Management LLC500,000$3.78M1.6%N/A1.390% Get the Latest News and Ratings for EPRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 2/18/2026 SummitTX Capital L.P.175,948$1.33M0.0%N/A0.489% 2/18/2026 Quadrature Capital Ltd43,186$326K0.0%N/A0.120% 2/18/2026 Boothbay Fund Management LLC156,331$1.18M0.0%N/A0.435% 2/17/2026 Ally Bridge Group NY LLC397,895$3.00M3.1%-56.5%1.106% 2/17/2026 Guardian Wealth Advisors LLC NC10,000$76K0.0%N/A0.028% 2/17/2026 Royal Bank of Canada196,277$1.48M0.0%-54.2%0.546% 2/16/2026 Aptus Capital Advisors LLC10,000$76K0.0%N/A0.028% 2/13/2026 Marshall Wace LLP158,133$1.19M0.0%N/A0.440% 2/13/2026 Ingalls & Snyder LLC77,400$584K0.0%+31.0%0.215% 2/12/2026 Jane Street Group LLC29,622$223K0.0%N/A0.082% 2/10/2026 Cibc World Market Inc.58,050$437K0.0%+287.0%0.161% 2/10/2026 Goldman Sachs Group Inc.58,058$438K0.0%+44.8%0.161% 2/9/2026 Geode Capital Management LLC13,899$105K0.0%N/A0.039% 1/1/2026 JPMorgan Chase & Co.16,467$97K0.0%-12.0%0.046% 11/17/2025 Alyeska Investment Group L.P.250,000$1.48M0.0%N/A0.695% 11/17/2025 Vivo Capital LLC1,350,000$7.97M0.6%N/A3.754% 11/17/2025 Velan Capital Investment Management LP352,000$2.08M2.0%N/A0.979% 11/17/2025 Integrated Wealth Concepts LLC12,000$71K0.0%N/A0.033% 11/17/2025 Bank of America Corp DE45,577$269K0.0%+262.9%0.127% 11/17/2025 Ally Bridge Group NY LLC915,000$5.40M3.3%N/A2.544% 11/14/2025 Raymond James Financial Inc.33,373$197K0.0%+173.3%0.093% 11/14/2025 Scotia Capital Inc.1,277,885$7.26M0.0%-1.1%3.554% 11/13/2025 UBS Group AG95,756$565K0.0%+155.4%0.266% 11/13/2025 Guardian Partners Inc.24,130$147K0.0%N/A0.067% 11/7/2025 Ingalls & Snyder LLC59,100$349K0.0%+58.9%0.164% 11/7/2025 JPMorgan Chase & Co.16,467$97K0.0%-12.0%0.046% 10/14/2025 TCI Wealth Advisors Inc.11,000$65K0.0%N/A0.031% 8/15/2025 Bank of America Corp DE12,559$72K0.0%+402.4%0.035% 8/13/2025 Quadrature Capital Ltd10,700$61K0.0%N/A0.030% 8/13/2025 Scotia Capital Inc.1,291,989$6.98M0.0%-16.8%3.593% I was right about SpaceX (Ad)Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.See how to claim your stake in SpaceX before the public can8/12/2025 JPMorgan Chase & Co.18,717$108K0.0%+593.2%0.052% 8/11/2025 TD Waterhouse Canada Inc.9,600$56K0.0%-90.9%0.027% 8/5/2025 Bank of Montreal Can37,250$215K0.0%-28.7%0.104% 7/31/2025 Ingalls & Snyder LLC37,200$214K0.0%N/A0.103% 5/15/2025Royal Bank of Canada342,828$1.13M0.0%+21.1%0.956% 5/9/2025Scotia Capital Inc.1,552,679$5.07M0.0%+11.6%4.331% 2/17/2025Millennium Management LLC10,000$31K0.0%N/A0.028% 2/13/2025Scotia Capital Inc.1,391,719$4.26M0.0%-0.3%3.907% 2/13/2025Raymond James Financial Inc.11,613$37K0.0%N/A0.033% 2/13/2025Bank of Montreal Can56,750$178K0.0%+15.2%0.159% 2/6/2025Raymond James Financial Inc.11,613$37K0.0%N/A0.033% 7/17/2024180 Wealth Advisors LLC13,000$34K0.0%N/A0.048% EPRX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of EPRX shares? During the previous two years, 34 institutional investors and hedge funds held shares of Eupraxia Pharmaceuticals. The most heavily invested institutionals were Affinity Asset Advisors LLC ($11.50M), Vivo Capital LLC ($7.97M), Scotia Capital Inc. ($7.26M), Redmile Group LLC ($5.07M), Rubric Capital Management LP ($5.00M), Ally Bridge Group NY LLC ($4.78M), and Ikarian Capital LLC ($4.61M).Learn more on Eupraxia Pharmaceuticals' institutional investors. Which institutional investors have been buying Eupraxia Pharmaceuticals' stock? Of the 33 institutional investors that purchased Eupraxia Pharmaceuticals' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Vivo Capital LLC ($1.35M), Affinity Asset Advisors LLC ($1.29M), Ally Bridge Group NY LLC ($1.18M), Redmile Group LLC ($700K), Rubric Capital Management LP ($691.17K), Ikarian Capital LLC ($610K), and Squadron Capital Management LLC ($500K). How much institutional buying is happening at Eupraxia Pharmaceuticals? Institutional investors have bought a total of 8,099,752 shares in the last 24 months. This purchase volume represents approximately $55.01M in transactions. Which of Eupraxia Pharmaceuticals' major shareholders have been selling company stock? The following institutional investors have sold Eupraxia Pharmaceuticals stock in the last 24 months: Ally Bridge Group NY LLC ($517.11K), Scotia Capital Inc. ($274.79K), Royal Bank of Canada ($232.53K), TD Waterhouse Canada Inc. ($95.39K), Bank of Montreal Can ($15K), and JPMorgan Chase & Co. ($4.50K). How much institutional selling is happening at Eupraxia Pharmaceuticals? Institutional investors have sold a total of 1,139,312 shares in the last 24 months. This volume of shares sold represents approximately $7.91M in transactions. Related Companies Precigen Institutional Ownership Amylyx Pharmaceuticals Institutional Ownership Atai Beckley Institutional Ownership Immatics Institutional Ownership Vir Biotechnology Institutional Ownership Immunocore Institutional Ownership MBX Biosciences Institutional Ownership Damora Therapeutics, Inc. Common Stock Institutional Ownership Urogen Pharma Institutional Ownership Compass Pathways Institutional Ownership This page (NASDAQ:EPRX) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
